References

  1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003; 349(6): 583-596. PubMed | Google Scholar

  2. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007; 357(11): 1083-93. PubMed | Google Scholar

  3. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006; 108(8): 2520-2530. PubMed | Google Scholar

  4. Jaccard A, Desport E, Mohty D, Bridoux F. Amylose AL. Rev Med Int. 2015; 36(2): 89-97. PubMed | Google Scholar

  5. Dispenzieri A, Gertz MA, Buadi F. What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Rev. 2012; 26(4): 137-4. Google Scholar

  6. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005; 79(4): 319-328. PubMed | Google Scholar

  7. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004; 22(18): 3751-. PubMed | Google Scholar

  8. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012; 30(36): 4541-9. PubMed | Google Scholar

  9. Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014; 124(15): 2325-32. PubMed | Google Scholar

  10. Jaccard A, Desport E, Mohty D, Bridoux F. AL amyloidosis. Rev Med Int. 2015; 36(2): 89-97. PubMed | Google Scholar

  11. Brambilla F, Lavatelli F, Di Silvestre D et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood. 2012; 119(8): 1844-1847. PubMed | Google Scholar

  12. Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012; 26(11): 2317-2325. PubMed | Google Scholar

  13. Palladini G, Foli A, Milani P, Russo P, Albertini R, Lavatelli F et al. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol. 2012; 87(5): 465-471. PubMed | Google Scholar

  14. Chaulagain CP, Comenzo RL. How we treat systemic light-chain amyloidosis. Clin Adv Hematol Oncol. 2015; 13(5): 315-24. PubMed | Google Scholar

  15. Palladini G, Russo P, Nuvolone M, Lavatelli F, Perfetti V, Obici L et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood. 2007; 110(2): 787-788. PubMed | Google Scholar

  16. Palladini G, Milani P, Foli A, Obici L, Lavatelli F, Nuvolone M et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: longterm results of a risk-adapted approach. Haematologica. 2014; 99(4): 743-50. PubMed | Google Scholar

  17. Kastritis E, Dimopoulos MA. Recent advances in the management of AL Amyloidosis. Br J Haematol. 2016; 172(2): 170-86. PubMed | Google Scholar

  18. Merlini G, Palladini G. Treating advanced cardiac damage in light chain amyloidosis: still an unmet need. Haematologica. 2014; 99(9): 1407-1409. PubMed | Google Scholar

  19. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012; 119(19): 4391-4. PubMed | Google Scholar